

## **TURN POLICIES AND PROCEDURES**

### ***Protocol for Selection of Target Compounds***

For each round of compound selection, the following procedures will apply:

1. Prior to each round of compound selection, the deadlines and timetables for completion of all steps in the nomination and selection process will be determined by the TURN Steering Committee and posted on the TURN website.
2. Nominations of compounds are sought from the academic community as well as the biotechnology and pharmaceutical industries. The Nomination Announcement will include a description of the nomination procedure, deadline for receipt of nominations, timetable for selection, and criteria for compound selection.
3. Nominated compounds will be reviewed by Compound Selection Committee of the Scientific Operations Unit of the TURN program. Candidate compounds will be reviewed by designated members of the Committee with expertise in the molecular target and drug class relevant for that compound. The members and consultants to the Compound Selection Committee are posted on the TURN website. Information about candidate compounds will be derived from public data bases, information provided by the compound's sponsor and references from the scientific literature.
4. Nominations are made through submission of a ***Compound Nomination Form*** to Jeffrey Lieberman, M.D., Chair, Compound Selection Committee of the Scientific Operations Unit of the TURN program via email to: [MC157@columbia.edu](mailto:MC157@columbia.edu).
5. Within 14 days of receipt of each nomination, the Chair, SOU and SOU Work Group will review the submission (Preliminary Screening) to insure it is responsive to the TURN Nomination Announcement and meets the required criteria (e.g. targets cognition in schizophrenia, scientific plausibility, IND or sufficiently close to IND-ready to be testable within required timelines). The SOU Chair, will report all compounds screened to the TURN Steering Committee monthly.
6. The SOU Chair, or his/her designee, will subsequently (within 14 days after screening or 28 days after submission) notify any sponsor of a rejected nomination and the reason for the rejection.
7. Prior to each round of compound reviews, the TURN Financial Disclosure Coordinator will provide the SOU Chair with a list of the financial interests of all SOU members. This list will be referred to at each stage of the review process to assure that the TURN Conflict of Interest Policy is followed.
8. The SOU Chair or his/her designee will subsequently (within 14 days after screening or 28 days after submission) notify the sponsor of a compound that will be considered for TURN. The sponsor will be asked to identify the appropriate contact person(s) for the sponsor from whom to obtain additional information about the compound.
9. If the SOU votes to accept the nomination of a compound the sponsor will be contacted and asked to submit the following: IDB; Clinical study reports (any conducted); Early PK data or PK/PD analyses not in IDB; and History of compound with company (brief summary of development work to date). This request will be accompanied with a list of all potential reviewers so that the sponsor can send their standard Confidentiality Agreements directly to reviewers and then send a hard copy of requested materials to reviewers once the CDA has been received. If further information is required before a decision on acceptance is made, information may be requested for a limited review by a select group of reviewers with expertise in the compound's target area and appropriate CDAs will be entered into in this phase.
10. If further CDAs are required at this or any phase of compound evaluation, the Office of the SOU Chair will coordinate with the sponsor.

11. The SOU Chair will assign each nominated and accepted compound to a primary reviewer who will be responsible for working with the compound sponsor to compile a dossier of information about the compound and for gathering additional information relevant to the compound's potential utility in alleviating cognitive deficits of schizophrenia. This information may be obtained from all available sources including databases and literature searches, in addition to contacts with source/sponsor. The SOU Chair and the reviewer may also decide to obtain additional information from selected outside consultants.
12. With information provided by the Sponsor and obtained from the scientific literature, the SOU reviewer will use all sources of information to complete a ***Candidate Compound Summary and Evaluation Form*** for the compound.
13. The SOU reviewer will provide a completed ***Candidate Compound Summary and Evaluation Form*** and dossier for the compound to the SOU Chair 4 weeks in advance of a scheduled SOU meeting to evaluate nominated compounds.
14. The SOU Chair will provide a ***Candidate Compound Summary and Evaluation Form*** to members of the SOU for each compound to be considered for inclusion in a TURN trial at least 3 weeks in advance of the scheduled TURN Compound Selection Committee meeting.
15. Based on data summarized in the ***Candidate Compound Summary and Evaluation Form*** and other available information in the compound dossier each member of the Turns Compound Selection Committee will score each compound using a ***Candidate Compound Scoring Form***. All ***Candidate Compound Scoring Forms*** are returned to the SOU Chair no later than two weeks prior to the face-to-face SOU meeting. Members also rate the suitability of each compound for different categories of clinical trials including clinical efficacy, pharmacodynamic, and pharmacokinetic trials.
16. The SOU Chair, or his/her designee, will compile and summarize scores from all SOU members for all rated compounds in a format suitable for presentation at the SOU meeting.
17. Final scoring of all compounds takes place at the SOU meeting, chaired by the SOU Chair and a consultant who is knowledgeable about the RAND Decision Method. Preliminary ratings are distributed and/or presented at the face-to-face meeting and items with substantial variation in scores are discussed with input from each primary reviewer. Following discussion of each nominated compound, SOU members complete a second and final ***Candidate Compound Scoring Form*** that reflects their final and best judgment informed by discussion at the meeting.
18. The SOU Chair summarizes the final scores and submits a ranked list of compounds within each study category (clinical efficacy, pharmacodynamic, pharmacokinetic) to the TURN Steering Committee.
19. The TURN Steering Committee uses the ranked list in each category to reach a decision regarding the preferred trials in each category.

**Forms/Guidelines Required:**

1. *Compound Nomination Form*
2. *Candidate Compound Summary and Evaluation Form*
3. *Candidate Compound Scoring Form*

*The tasks described in this document and associated deadlines are summarized in below table.*

**TURN Compound Selection Timeline/Deadlines**

<b>TASK/ Form</b>	<b>Responsible Person</b>	<b>Deadline</b>
Compound Nomination Form	All sources	
Preliminary Screen (First Cut)	SOU Chair and SOU Work Group	14 days after receipt
Notification of Sponsor that nomination is rejected or that Reviewer or designee will contact sponsor to gather detailed information.	Office of SOU Chair	14 days after receipt
Circulate, obtain signatures, and provide Confidentiality Agreements to sponsor	Office of SOU Chair	
Assignment of accepted compounds to primary SOU Reviewer.	SOU Chair	
Completion of <i>Target Product Profile, Candidate Compound Summary and Evaluation Form</i> and return to SOU Chair	SOU Primary Reviewer with assistance from sponsor	
Distribution of all <i>Compound Summary and Evaluation Form and blank Candidate Compound Scoring Forms</i> to each member TCSC	SOU Chair	
Completion of <i>Candidate Compound Scoring Form</i> and return to SOU Chair	TCSC Members	
Analysis of all <i>Candidate Compound Scoring Form</i> for presentation at TCSC meeting.	Chair, SOU	
TCSC Meeting – Second (Final) Scoring of all Candidate Compounds	TSCS, Chaired by SOU Chair and RAND Method Expert	
Delivery of final prioritized candidate compound list to TURN Steering Committee	SOU Chair	
Final Selection of Compound	TURN Steering Committee, TSC Chair	